Journal of Clinical Psychiatry

Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.  82. 2021

Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.  82. 2021

A Randomized, Placebo-Controlled Trial of Mirtazapine for the Treatment of Posttraumatic Stress Disorder in Veterans.  81. 2020

A phase 2, randomized, double-blind, placebo-controlled ST of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY).  80. 2019

Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial.  80. 2019

Efficacy of ziprasidone augmentation of escitalopram for cognitive symptoms of major depressive disorder.  79:55-59. 2018

Clinical and genetic predictors of delayed remission after multiple levels of antidepressant treatment: Toward early identification of depressed individuals for advanced care options.  78:e1291-e1298. 2017

Ziprasidone augmentation of escitalopram for major depressive disorder: Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study.  78:449-455. 2017

Long-Term Efficacy, Safety, and Tolerability of l-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors: A 12-Month, Open-Label Study Following a Placebo-Controlled Acute Study.  77:654-660. 2016

Sleep disturbance in chronic military-related PTSD: Clinical impact and response to adjunctive risperidone in the veterans affairs cooperative study #504.  77:483-491. 2016

Behavioral interventions for antipsychotic medicationassociated obesity: A randomized, controlled clinical trial.  77:e183-e189. 2016

Baseline disability and poor functioning in Bipolar disorder predict worse outcomes: Results from the Bipolar CHOICE study.  77:100-108. 2016

Bipolar CHOICE (clinical health outcomes initiative in comparative effectiveness): A pragmatic 6-month trial of lithium versus quetiapine for Bipolar disorder.  77:90-99. 2016

Association of obesity and inflammatory marker levels on treatment outcome: Results from a double-blind, randomized study of adjunctive l-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.  76:1635-1641. 2015

Reply to commentary by rothschild: "A blood test for depression?".  76:e1038. 2015

Factors affecting exits from homelessness among persons with serious mental illness and substance use disorders.  76:e469-e476. 2015

What are the comparative benefits and harms of augmentation treatments in major depression?.  76:e531-e533. 2015

MDDScore: Confirmation of a blood test to aid in the diagnosis of major depressive disorder.  76:e199-e206. 2015

A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.  73:1541-1547. 2012

A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure.  72:1002-1007. 2011

Challenges and algorithm-guided treatment in major depressive disorder..  72. 2011

Crisis of confidence: antidepressant risk versus benefit..  72. 2011

A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.  72:1405-1412. 2011

Evidence for the use of l-methylfolate combined with antidepressants in MDD..  72. 2011

Moderators of antidepressant response in major depression..  72. 2011

Performance improvement CME: algorithms and EMRs in depression..  72. 2011

The current crisis of confidence in antidepressants.  72:27-33. 2011

Using algorithms and computerized decision support systems to treat major depression..  72. 2011

Using moderator-based algorithms and electronic medical records to achieve optimal outcomes in depression..  72. 2011

St John's wort (Hypericum perforatum) in major depression.  70:23-27. 2009

Long-term management of depression: Tips for adjusting the treatment plan as the patient's needs change.  70:32-37. 2009

Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: A blinded, randomized study.  70:450-457. 2009

Family history of depression and therapeutic outcome: Findings from STAR*D.  70:185-195. 2009

Pathophysiologic mechanisms of fibromyalgia and its related disorders.  69:6-13. 2008

Do Atypical Antipsychotics Effectively Treat Co-Occurring Bipolar Disorder and Stimulant Dependence?.  69:1257-1266. 2008

Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial.  69:1257-1266. 2008

Evaluating and diagnosing fibromyalgia and comorbid psychiatric disorders..  69. 2008

Multidisciplinary care and stepwise treatment for fibromyalgia..  69. 2008

The history and current state of antidepressant clinical trial design: A call to action for proof-of-concept studies.  69:1513-1528. 2008

Augmentation strategies to increase antidepressant efficacy.  68:18-22. 2007

A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex.  68:1546-1551. 2007

Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort.  68:1931-1938. 2007

Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A meta-analysis.  68:826-831. 2007

Dr. Shelton replies [4].  68:1619. 2007

Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study.  68:1071-1077. 2007

Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study.  68:1014-1023. 2007

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: Outcomes from the 2-year and combined maintenance phases.  68:1246-1256. 2007

Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research.  67:27-30. 2006

The nature of the discontinuation syndrome associated with antidepressant drugs.  67:3-7. 2006

A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.  67:1674-1681. 2006

Use of treatment algorithms for depression.  67:1458-1465. 2006

Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance.  66:1289-1297. 2005

Psychiatric genetics: A survey of psychiatrists' knowledge, opinions, and practice patterns.  66:821-830. 2005

Risperidone and paroxetine given singly and in combination for bipolar depression.  65:1715-1719. 2004

The dual-action hypothesis: Does pharmacology matter?.  65:5-10. 2004

The effectiveness of St. John's wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication.  65:1114-1119. 2004

Risperidone in the treatment of delirium: Results from a prospective open-label trial.  65:662-667. 2004

The use of antidepressants in novel combination therapies.  64:14-18. 2003

Mechanisms of action in the treatment of anxiety.  62:10-15. 2001

Introduction: Remission of anxiety-related disorders.  62:3-4. 2001

Measuring patient symptom change on rural psychiatry units: Utility of the symptom checklist-90 revised.  61:493-497. 2000

Mood-stabilizing drugs in depression.  60:37-42. 1999

Treatment options for refractory depression.  60:57-63. 1999

The distribution of body mass index among individuals with and without schizophrenia.  60:215-220. 1999

Treatment of schizophrenia 1999.  60:3-80. 1999

Update on the management of bipolar illness.  59:484-495. 1998

The undertreatment of dysthymia.  58:59-65. 1997

Fluoxetine in dementia of the Alzheimer's type: Prominent adverse effects and failure to improve cognition [1].  55:161. 1994

The effects of race and comorbidity on clinical diagnosis in patients with psychosis.  54:96-102. 1993